In VivoWhen Thijs Spoor was weighing his next career move in 2022, one option stood out despite its humble appearance. While other opportunities offered larger funding rounds and flashier platforms, a small
ScripUCB has become the latest Europe drugmaker to pledge major manufacturing investments in the US amid the pressure being put on the pharmaceutical sector by President Trump administration to move more d
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Taiho Sends Benz LSD1 Inhibitor Fo
ScripRiding high on the wave of its dual GIP/GLP-1 agonist, tirzepatide, Eli Lilly awarded its CEO the highest total remuneration package of the top 12 big pharma companies in 2024. David Ricks’s total com